Threshold Pharmaceuticals has released the results of its clinical trial of TH-302 for patients with advanced solid tumours and said the data supports the need for an additional study.
The clinical trial was a Phase I/II, three arm, multicentre dose escalation and dose expansion trial to determine the safety, efficacy and pharmacokinetics of TH-302 in combination with gemcitabine, docetaxel or pemetrexed, the company said.
Threshold Pharmaceuticals managing director John Hurd said while limited in number, the results in patients with first-line pancreatic cancer are notable as compared to historical standards.
“Historically, the response rates in first-line pancreatic cancer with gemcitabine have been less than 10%. We believe that the safety and activity data supports an additional study of TH-302 in combination with full-dose gemcitabine to determine if TH-302 adds clinical benefit to patients fighting pancreatic cancer,” Hurd said.